solute carrier family 45 member 3Genealiases: IPCA-2 · IPCA-6 · IPCA-8 · IPCA6 · PCANAP2 · PCANAP6
Q-omics provides the consensus-scored SLC45A3 profile across patient tissues and cancer cell-line models. SLC45A3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC45A3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SLC45A3 RNA expression shows 18,459 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where SLC45A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC45A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC45A3 survival associations across molecular data types. SLC45A3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC45A3 RNA expression–survival associations across cancer types. High SLC45A3 expression shows unfavorable associations in UVM, KICH, UCEC, SKCM and CESC, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC45A3 RNA expression.
This table summarizes SLC45A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SLC45A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC45A3 shows lower tumor expression in KICH, KIRC and UCEC and higher tumor expression in HNSC, BLCA and ESCA. The KICH box plot shows higher SLC45A3 RNA expression in normal versus tumor tissue (log2 FC = −2.973, t-test p < 0.001).
This table shows molecular features associated with SLC45A3 in patient tissues and cancer cell lines. In patient samples, SLC45A3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC45A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
